Kenvue (KVUE) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
3 Feb, 2026Opening remarks and agenda
Chair welcomed stockholders, introduced board and management, and outlined the meeting's official business.
Rules of conduct and quorum confirmation were addressed, with 78.2% of shares represented by proxy.
Shareholder proposals
Three proposals were presented: approval of the Merger Agreement, an Advisory Compensation Proposal, and an Adjournment Proposal.
The board unanimously recommended approval of all three proposals.
Overview of voting outcomes
Preliminary results showed approval of the Merger Proposal by 40% of outstanding shares and a majority of voting power present.
The Advisory Compensation Proposal was also approved; the Adjournment Proposal was not called due to the merger's approval.
Final vote results will be reported in a Form 8-K filing with the SEC.
Latest events from Kenvue
- Third consecutive quarter of sales growth, margin pressure, and Kimberly-Clark merger progress.KVUE
Q2 2026 - All director nominees, executive pay, and auditor ratification were approved by shareholders.KVUE
AGM 2026 - Net income jumped 47% on higher sales and margins, with restructuring and a major merger pending.KVUE
Q1 2026 - Shareholders will vote on a merger, director elections, executive pay, and auditor ratification.KVUE
Proxy filing - Proxy statement solicits shareholder votes for annual meeting with no filing fee required.KVUE
Proxy filing - Q4 sales and margins improved, but full year sales declined; Kimberly-Clark deal pending.KVUE
Q4 2025 - A $48.7B merger forms a global health leader, targeting $2.1B in synergies by 2026.KVUE
M&A Announcement - Q2 saw 1.5% organic growth, margin expansion, and a $488M impairment hit net income.KVUE
Q2 2024 - Q1 2025 net sales fell 3.9% and adjusted EPS was flat, pressured by tariffs and FX.KVUE
Q1 2025